{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:23:25Z","timestamp":1789421005257,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To optimize treatment of inflammatory diseases, interest in the measurement of anti\u2013tumor necrosis factor alpha (anti-TNF\u03b1) serum drug concentrations is increasing. Preferably, assays for the detection of these drugs should be compared using the same reference material. In this study, 2 commercially available enzyme-linked immunosorbent assays (ELISAs) and a commercially available bioassay for the determination of anti-TNF\u03b1 drugs are compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Serum samples from infliximab-, adalimumab-, and etanercept-treated patients, control samples from ustekinumab-treated patients, and healthy donors were obtained. ELISAs manufactured by Sanquin and Theradiag and the iLite reporter gene\u2013based bioassay from Biomonitor were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Sanquin, Theradiag, and iLite assays concordantly (100%) detected infliximab, adalimumab, and etanercept in the relevant patient groups. The Sanquin ELISAs specifically detected the anti-TNF\u03b1 drug they were designed for, whereas the Theradiag and iLite showed cross-reactivity with other anti-TNF\u03b1 drugs. Ustekinumab was not detected in any of the assays. Sanquin, Theradiag, and iLite exhibited linear quantitative correlation for all drug concentration assays. However, there were statistically significant quantitative differences in measured concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>All 3 commercially available assays seem suitable for therapeutic drug monitoring of anti-TNF\u03b1 drugs, allowing sensitive and comparable detection of infliximab, adalimumab, and etanercept concentrations, however with differences in specificity and recovery.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000310","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T16:15:19Z","timestamp":1461773719000},"page":"432-438","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations"],"prefix":"10.1097","volume":"38","author":[{"given":"Ji S.","family":"van Bezooijen","sequence":"first","affiliation":[{"name":"Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B. A.","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[{"name":"Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco W. J.","family":"Schreurs","sequence":"additional","affiliation":[{"name":"Immunology, University Medical Center, Erasmus MC, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/jdv.12549","article-title":"Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies","volume":"28","author":"Carrascosa","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/FTD.0b013e318295f6b2","article-title":"Monitoring antigen-specific biologics: current knowledge and future prospects","volume":"35","author":"Zandvliet","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ajg.2014.110","article-title":"Toward a personalized medicine approach to the management of inflammatory bowel disease","volume":"109","author":"Mosli","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","article-title":"Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation","volume":"72","author":"van Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"R7-20230814","article-title":"Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits","author":"Schmitz","year":"2015","journal-title":"Clin Chem Lab Med."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/apt.12130","article-title":"Letter: detection of infliximab levels and anti-infliximab antibodies\u2013comparison of three different assays","volume":"37","author":"Parussini","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.12128","article-title":"Letter: detection of infliximab levels and anti-infliximab antibodies\u2013comparison of three different assays; authors' reply","volume":"37","author":"Buurman","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","article-title":"Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment","volume":"151","author":"Menting","year":"2015","journal-title":"JAMA Dermatol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FTD.0b013e31828d23c3","article-title":"Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease","volume":"35","author":"Steenholdt","year":"2013","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201608000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:03:48Z","timestamp":1692050628000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201608000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000310","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}